If this is a buyout in process, what would be the likely price? It seems too early for price talk but this may just be the first step in a process that will finalize after the EPIC release.
Biotechsupplier1 - the preliminary data Dr. Johnson refers to is EPIC preliminary data? I am having some difficulty finding that data report. I would like to view it online.
Something positive for you. Shorts just dropped near 700K. Going down from 1,704,000 to 1,060,200 or over 40%. How much more will shorts be down in the next short interest report on May 10th? Would you want to be short with the EPIC report about to be released?
Thanks.....as of February 29, 2016:
"It is important to remind everyone that EPIC is a double-blinded study, which means that neither Mast, the physician investigators, nor the patients involved in the clinical trial know which patients received vepoloxamer and which received placebo. The EPIC study data will remain blinded to Mast, including to its management and employees, after the last patient’s last visit and throughout the completion of the quality assurance and quality control process. For those who are unfamiliar with the process, following the last patient’s protocol-designated 30-day safety observation period following hospital discharge, there is an extensive and rigorous review of the blinded data for quality control, leading to database lock for the study. Study unblinding then will be performed only by the external study biostatistician. After the statistician’s work is complete, Mast will be notified of the top-line outcome of the study from the biostatistician. At that point, Mast will be able to report study results to our stockholders. Consistent with our guidance, we expect to announce top-line results from the EPIC study next quarter and we hope to narrow that guidance as we get closer to the announcement."
There is a requirement to report to the SEC when a 5% or greater 13G filer falls below the 5% level (a change in disclosed information) or when a 13G filer rises up to the 5% or greater level.
Does the board have an estimate for when the report will be out? This was the PR on January 7, 2016:
"We are pleased to report that more than 90% of the planned 388 patients have been enrolled in EPIC, the largest sickle cell crisis intervention study ever conducted," stated Brian M. Culley, Chief Executive Officer. "Participation in EPIC has been outstanding with more than 75 sites in 14 countries and more than two-thirds of those sites located in the U.S. We expect to complete enrollment next month and after the final enrolled patient's 30-day observation period, the process of blinded data review and quality control will begin, leading thereafter to database lock and unblinding of the study data."
The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to complete patient enrollment in February. Consistent with prior guidance, the Company expects to report top-line results in the second quarter of 2016.
"How do you know they are still holding that many shares as of 4/19 ?"
Sabby is an over 5% holder as reported and if Sabby sells or buys more they are required to file another 13G within 10 days. They have not filed so it can be assumed that they still hold 19,251,250 shares of MSTX with the right to exercise additional warrant shares at 42 cents. Only the shorts have changed their numbers in the last few days and that is down about 700K and could be going down more in the next short interest report on May 10th.
"Nasdaq still has not updated short interest for MSTX. In fact they have deleted the short interest history."
MSTX new short interest is 1,060,200 down from 1,700,000
by Zacks Equity Research Published on April 12, 2016 |
As of late, it has definitely been a great time to be an investor in Mast Therapeutics, Inc. (MSTX - Snapshot Report). The stock has moved higher by 15% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider MSTX’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as MSTX has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
You need to read the VVUS changes more closely. There will be no announcement for Stendra by the end of March. The CEO updated the news/announcement for June and this is in regard to the entire company's future. Strategic financial changes are in the making for this small stock. and it all started with the entry of the Icahn Enterprise that wants a sure thing. TEVA and or others are playing with the options. TEVA is the better match as a generic maker but there are others that can fit. Don't let the TEVA announcement in Israel mislead you.
VVUS is up for sale and management already said news by June. Of course, it can be much sooner but that's the target date. If this is upsetting for you then think about selling. North Tide wants more shares.
Just so you can be better educated - Icahn Enterprises is what is functioning in this company. Icahn hires his managers to do the work in 'his' name and that has been the case for as long as Icahn has been at work in the market. Invest with your eyes open.
"came in to collect interest only"
Amateur - you have no clue why Icahn 'enterprises' is here - but it's not for the rent.
Another 2 million short shares covered in yesterday's short report. The stock will trade with little movement until buyout news.
You're pushing too hard. The stock not likely to move under one but gyrate under 1.10 for a while until the buyout news is ready. CEO says news by June but anytime before that is possible.
Definitely - selling this company soon is the priority for Icahn who may be the specialist financial adviser the CEO refers to. Timing is everything including patent expiration.